AKESO (09926) saw its shares rise nearly 5% during morning trading. At the time of writing, the stock was up 4.22%, trading at HK$106.2, with a turnover of HK$456 million. The increase follows news that on February 25, the company submitted a New Drug Application (NDA) for its self-developed IL-4Rα monoclonal antibody (Mandoqi Monoclonal Antibody, AK120) to the National Medical Products Administration (NMPA), which has been accepted. The drug is intended for the treatment of moderate-to-severe atopic dermatitis (AD). Mandoqi Monoclonal Antibody is the fourth non-oncology drug developed by AKESO to enter the marketing application stage. Previously, the PCSK9 monoclonal antibody Inusimab, the IL-12/IL-23 monoclonal antibody Yiroqi Monoclonal Antibody, and the IL-17A monoclonal antibody Gumoqi Monoclonal Antibody have been successively approved or submitted for market approval, forming a self-developed immunology product portfolio covering areas such as cardiovascular metabolism, dermatology, and rheumatology.